Windtree Therapeutics, Inc. Net Debt

Net Debt of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt growth rates and interactive chart. Net debt is the sum of all interest-bearing debt (short-term and long-term) minus cash and short-term investments. A positive number indicates the company's total debt exceeds its cash and short-term investments balances, while a negative number means the company has more cash than its total debt. This figure is also used in Enterprise value calculation.


Highlights and Quick Summary

  • Net Debt for the quarter ending June 29, 2020 was $-10.8 Million (a -412.89% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt decreased by -158.88%
  • Annual Net Debt for 2019 was $-2.81 Million (a 29.33% increase from previous year)
  • Annual Net Debt for 2018 was $-2.17 Million (a -116.47% decrease from previous year)
  • Annual Net Debt for 2017 was $13.2 Million (a -32.08% decrease from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt of Windtree Therapeutics, Inc.

Most recent Net Debtof WINT including historical data for past 10 years.

Interactive Chart of Net Debt of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Net Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-10.8 $3.45
2019 $-2.81 $18.35 $14.38 $6.9 $-2.81
2018 $-2.17 $19.61 $16.86 $15.65 $-2.17
2017 $13.19 $25.85 $22.47 $16.98 $13.19
2016 $19.41 $12.62 $4.67 $-4.4 $19.41
2015 $-13.72 $-21.31 $-4.62 $-14.68 $-13.72
2014 $-24.35 $-35.06 $-46.19 $-57.03 $-24.35
2013 $-67.79 $-14.69 $-24.87 $-20.16 $-67.79
2012 $-26.68 $-35.83 $-45.76 $-54.53 $-26.68
2011 $-9.9 $-15.1 $-21.19 $-27.26 $-9.9
2010 $-9.77 $-14.13 $-18.62 $-12.75 $-9.77

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.